Alumis readies $300 million IPO ahead of Phase 3 trial for plaque psoriasis drug
By Steve Gelsi
California-based biopharmaceutical company plans to trade on the Nasdaq under the symbol ALMS
Alumis Inc. on Monday said it plans to offer 17.65 million shares at an estimated price range of $16 to $18 per share in its upcoming initial public offering.
At the midpoint of its range, Alumis would raise about $300 million with underwriters ?Morgan Stanley, Leerink Partners??, Cantor and ??Guggenheim Securities.
Alumis plans to trade on the Nasdaq under the symbol ALMS.
Based in South San Francisco, Calif., Alumis is a clinical-stage biopharmaceutical developing two tyrosine kinase 2, or TYK2, inhibitors: ESK-001 and A-005.
On ESK-001, Alumis is planning multiple Phase 3 clinical trials in the second half of 2024 as a treatment for moderate to severe plaque psoriasis, a skin disease.
The company said ESK-001 has demonstrated "significant therapeutic effect" for patients in its Phase 2 program.
Alumis also expects results in 2026 for an evaluation of ESK-100 for a Phase 2 clinical trial in patients with systemic lupus erythematosus.
The company has also launched a Phase 1 trial of A-005 as an allosteric TYK2 inhibitor to help treat neuroinflammatory and neurodegenerative diseases, with initial results expected by the end of 2024.
Martin Babler has been president, chairman and chief executive of Alumis since 2021.
He previously worked as chief executive of Principia Biopharma Inc., a biotechnology company acquired by Sanofi S.A. (FR:SAN) in 2020.
Foresite Capital Management, Baker Brothers Life Sciences LP and AyurMaya Capital Management Fund LP are listed as principal shareholders in the Alumis IPO.
-Steve Gelsi
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
06-24-24 1140ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations